NASDAQ:PMVP

PMV Pharmaceuticals Competitors

$33.30
-0.76 (-2.23 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$33.24
Now: $33.30
$35.36
50-Day Range
$30.66
MA: $36.96
$43.10
52-Week Range
$29.44
Now: $33.30
$63.22
Volume190,312 shs
Average Volume159,512 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

PMV Pharmaceuticals (NASDAQ:PMVP) Vs. SRPT, ALLK, BPMC, PRGO, SDGR, and GLPG

Should you be buying PMVP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to PMV Pharmaceuticals, including Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), and Galapagos (GLPG).

Sarepta Therapeutics (NASDAQ:SRPT) and PMV Pharmaceuticals (NASDAQ:PMVP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Sarepta Therapeutics and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
PMV PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Sarepta Therapeutics and PMV Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million14.71$-715,080,000.00($9.71)-7.26
PMV PharmaceuticalsN/AN/AN/AN/AN/A

PMV Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics.

Analyst Ratings

This is a breakdown of current recommendations for Sarepta Therapeutics and PMV Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191202.50
PMV Pharmaceuticals01302.75

Sarepta Therapeutics presently has a consensus price target of $150.4762, indicating a potential upside of 113.32%. PMV Pharmaceuticals has a consensus price target of $38.00, indicating a potential upside of 14.11%. Given Sarepta Therapeutics' higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than PMV Pharmaceuticals.

Institutional and Insider Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Sarepta Therapeutics beats PMV Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and PMV Pharmaceuticals (NASDAQ:PMVP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Allakos and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
PMV PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Allakos and PMV Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-55.56
PMV PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Allakos and PMV Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
PMV Pharmaceuticals01302.75

Allakos presently has a consensus price target of $181.50, indicating a potential upside of 72.86%. PMV Pharmaceuticals has a consensus price target of $38.00, indicating a potential upside of 14.11%. Given Allakos' stronger consensus rating and higher probable upside, research analysts clearly believe Allakos is more favorable than PMV Pharmaceuticals.

Institutional and Insider Ownership

65.4% of Allakos shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 44.8% of Allakos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Allakos beats PMV Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and PMV Pharmaceuticals (NASDAQ:PMVP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Institutional and Insider Ownership

69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Blueprint Medicines and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
PMV PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Blueprint Medicines and PMV Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million82.05$-347,690,000.00($7.27)-12.95
PMV PharmaceuticalsN/AN/AN/AN/AN/A

PMV Pharmaceuticals has lower revenue, but higher earnings than Blueprint Medicines.

Analyst Ratings

This is a breakdown of current recommendations for Blueprint Medicines and PMV Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
PMV Pharmaceuticals01302.75

Blueprint Medicines presently has a consensus price target of $111.00, indicating a potential upside of 17.88%. PMV Pharmaceuticals has a consensus price target of $38.00, indicating a potential upside of 14.11%. Given Blueprint Medicines' higher probable upside, research analysts clearly believe Blueprint Medicines is more favorable than PMV Pharmaceuticals.

Summary

Blueprint Medicines beats PMV Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and PMV Pharmaceuticals (NASDAQ:PMVP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

82.7% of Perrigo shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 0.3% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Perrigo and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
PMV PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Perrigo and PMV Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.12$146.10 million$4.0310.06
PMV PharmaceuticalsN/AN/AN/AN/AN/A

Perrigo has higher revenue and earnings than PMV Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings for Perrigo and PMV Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
PMV Pharmaceuticals01302.75

Perrigo presently has a consensus target price of $52.00, indicating a potential upside of 28.30%. PMV Pharmaceuticals has a consensus target price of $38.00, indicating a potential upside of 14.11%. Given Perrigo's higher probable upside, equities analysts plainly believe Perrigo is more favorable than PMV Pharmaceuticals.

Summary

Perrigo beats PMV Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and PMV Pharmaceuticals (NASDAQ:PMVP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

41.3% of Schrödinger shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Schrödinger and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
PMV PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Schrödinger and PMV Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million60.48$-24,570,000.00N/AN/A
PMV PharmaceuticalsN/AN/AN/AN/AN/A

PMV Pharmaceuticals has lower revenue, but higher earnings than Schrödinger.

Analyst Recommendations

This is a breakdown of current ratings for Schrödinger and PMV Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
PMV Pharmaceuticals01302.75

Schrödinger presently has a consensus target price of $85.50, indicating a potential upside of 15.70%. PMV Pharmaceuticals has a consensus target price of $38.00, indicating a potential upside of 14.11%. Given Schrödinger's higher probable upside, equities analysts plainly believe Schrödinger is more favorable than PMV Pharmaceuticals.

Summary

PMV Pharmaceuticals beats Schrödinger on 4 of the 6 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and PMV Pharmaceuticals (NASDAQ:PMVP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Profitability

This table compares Galapagos and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
PMV PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Galapagos and PMV Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.08$167.83 million$5.4614.25
PMV PharmaceuticalsN/AN/AN/AN/AN/A

Galapagos has higher revenue and earnings than PMV Pharmaceuticals.

Institutional & Insider Ownership

11.2% of Galapagos shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Galapagos and PMV Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos211402.12
PMV Pharmaceuticals01302.75

Galapagos presently has a consensus target price of $143.7273, indicating a potential upside of 84.72%. PMV Pharmaceuticals has a consensus target price of $38.00, indicating a potential upside of 14.11%. Given Galapagos' higher probable upside, equities analysts plainly believe Galapagos is more favorable than PMV Pharmaceuticals.

Summary

PMV Pharmaceuticals beats Galapagos on 5 of the 9 factors compared between the two stocks.


PMV Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.